The effective application of biased signaling to new drug discovery

Molecular Pharmacology

Volumn 88, Issue 6, 2015, Pages 1055-1061

  Kenakin, Terry ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGONIST; AGONIST POTENCY; ALLOSTERISM; ARTICLE; BIASED SIGNALING; DRUG DEVELOPMENT; DRUG RESPONSE; DRUG SCREENING; IN VITRO STUDY; INTRINSIC ACTIVITY; PHARMACEUTICS; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; PHYSIOLOGY; PROCEDURES; TRENDS;

LIGAND; NARCOTIC ANALGESIC AGENT;

ANALGESICS, OPIOID; ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; SIGNAL TRANSDUCTION;

EID: 84947500240     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099770     Document Type: Article

References (66)

1. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32-49.
2. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
3. Bradley SJ, Langmead CJ, Watson JM, and Challiss RA (2011) Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 79:874-885.
4. Casella I, Ambrosio C, Grò MC, Molinari P, and Costa T (2011) Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling. Biochem J 438:191-202.
5. Charfi I, Audet N, Bagheri Tudashki H, and Pineyro G (2015) Identifying ligandspecific signalling within biased responses: focus on d opioid receptor ligands. Br J Pharmacol 172:435-448.
6. Christmanson L, Westermark P, and Betsholtz C. (1994) Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem Biophys Res Commun 205:1226-1235.
7. Cook AE, Mistry SN, Gregory KJ, Furness SG, Sexton PM, Scammells PJ, Conigrave AD, Christopoulos A, and Leach K (2015) Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics. Br J Pharmacol 172: 185-200.
8. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, and Christopoulos A (2012) Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 153:1232-1241.
9. De Wire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen X-T, Pitis PM, Gotchev D, and Yuan C et al. (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717.
10. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
11. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754.
12. 3 muscarinic receptors in guinea pig ileum and transfected cells. J Pharmacol Exp Ther 289:981-992.
13. Ehlert FJ, Griffin MT, and Suga H (2011) Analysis of functional responses at G protein-coupled receptors: estimation of relative affinity constants for the inactive receptor state. J Pharmacol Exp Ther 338:658-670.
14. Evans BA, Sato M, Sarwar M, Hutchinson DS, and Summers RJ (2010) Liganddirected signalling at β-adrenoceptors. Br J Pharmacol 159:1022-1038.
15. Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT, Manen D, and Bouxsein ML (2005) Bone response to intermittent parathyroid hormone is altered in mice null for β-arrestin2. Endocrinology 146:1854-1862.
16. Figueroa KW, Griffin MT, and Ehlert FJ (2009) Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328: 331-342.
17. Frauenfelder H, Sligar SG, and Wolynes PG (1991) The energy landscapes and motions of proteins. Science 254:1598-1603.
18. Freire E (1998) Statistical thermodynamic linkage between conformational and binding equilibria. Adv Protein Chem 51:255-279.
19. Galandrin S and Bouvier M (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
20. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, and Luttrell LM et al. (2006) Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864.
21. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, and Luttrell LM (2009) A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1.
22. 15. J Pharmacol Exp Ther 321:1193-1207.
23. Hilser VJ, Dowdy D, Oas TG, and Freire E (1998) The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc Natl Acad Sci USA 95:9903-9908.
24. Hilser VJ, García-Moreno E B, Oas TG, Kapp G, and Whitten ST (2006) A statistical thermodynamic model of the protein ensemble. Chem Rev 106:1545-1558.
25. Hilser VJ and Thompson EB (2007) Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc Natl Acad Sci USA 104:8311-8315.
26. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, and Johnson GL (1998) [D-Arg1, D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273:3097-3104.
27. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
28. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
29. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
30. Kenakin T (2013) New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol 168:554-575.
31. Kenakin TP and Morgan PH (1989) Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol 35:214-222.
32. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
33. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216.
34. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, and Nichols DE et al. (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptortransfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189.
35. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
36. Kudlacek O, Waldhoer M, Kassack MU, Nickel P, Salmi JI, Freissmuth M, and Nanoff C (2002) Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain. Naunyn Schmiedebergs Arch Pharmacol 365:8-16.
37. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
38. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, and Galzi JL (2007) A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 21:2124-2134.
39. Manning DR (2002) Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol 62:451-452.
40. Mary S, Damian M, Louet M, Floquet N, Fehrentz J-A, Marie J, Martinez J, and Banères J-L (2012) Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci USA 109:8304-8309.
41. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, and Kostenis E (2005) Identification of indole derivatives exclusively interfering with a G proteinindependent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 68:393-402.
42. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, and Charlton SJ et al. (2010) μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-766.
43. Nickolls SA, Waterfield A, Williams RE, and Kinloch RA (2011) Understanding the effect of different assay formats on agonist parameters: a study using the μ-opioid receptor. J Biomol Screen 16:706-716.
44. 4 receptor Gαi - and β-arrestin2-biased ligands. Mol Pharmacol 82:1174-1182.
45. Onaran HO and Costa T (1997) Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci 812:98-115.
46. Onaran HO, Scheer A, Cotecchia S, and Costa T (2000) A look at receptor efficacy. From the signalling network of the cell to the intramolecular motion of the receptor, in The Pharmacology of Functional, Biochemical, and Recombinant Systems (Kenakin TP and Angus JA eds) pp 217-280, Springer, Heidelberg, Germany.
47. Onaran HO and Costa T (2012) Where have all the active receptor states gone? Nat Chem Biol 8:674-677.
48. Peters MF, Knappenberger KS, Wilkins D, Sygowski LA, Lazor LA, Liu J, and Scott CW (2007) Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J Biomol Screen 12:312-319.
49. Peters MF and Scott CW (2009) Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 14:246-255.
50. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, and Walker G et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495.
51. Raehal KM, Walker JK, and Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195-1201.
52. Rees S, Morrow D, and Kenakin T (2002) GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8:261-268.
53. Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064.
54. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
55. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu J-C, and Olefsky JM (2008) β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic b cells. Proc Natl Acad Sci USA 105:6614-6619.
56. Stahl EL, Zhou L, Ehlert FJ, and Bohn LM (2015) A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Mol Pharmacol 87: 866-877 10.1124/mol.114.096503.
57. Stockton JM, Birdsall NJ, Burgen AS, and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23: 551-557.
58. Strachan RT, Sciaky N, Cronan MR, Kroeze WK, and Roth BL (2010) Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity. Mol Pharmacol 77:327-338.
59. Tran JA, Chang A, Matsui M, and Ehlert FJ (2009) Estimation of relative microscopic affinity constants of agonists for the active state of the receptor in functional studies on M2 and M3 muscarinic receptors. Mol Pharmacol 75:381-396.
60. Violin JD, Dewire SM, Barnes WG, and Lefkowitz RJ (2006) G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem 281:36411-36419.
61. Violin JD, De Wire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
62. Watson C, Chen G, Irving P, Way J, Chen WJ, and Kenakin T (2000) The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58: 1230-1238.
63. Whistler JL and von Zastrow M (1999) Dissociation of functional roles of dynamin in receptor-mediated endocytosis and mitogenic signal transduction. J Biol Chem 274:24575-24578.
64. White KL, Scopton AP, Rives M-L, Bikbulatov RV, Polepally PR, Brown PJ, Kenakin T, Javitch JA, Zjawiony JK, and Roth BL (2014) Identification of novel functionally selective κ-opioid receptor scaffolds. Mol Pharmacol 85:83-90.
65. Yan F, Mosier PD, Westkaemper RB, and Roth BL (2008) Ga-subunits differentially alter the conformation and agonist affinity of κ-opioid receptors. Biochemistry 47: 1567-1578.
66. Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, and Madoux F et al. (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288: 36703-36716.